Compounds for the treatment of addiction
AssigneeGilead Sciences, Inc.
InventorsCarina E. Cannizzaro, Michael Graupe, Juan A. Guerrero, Yafan Lu, Robert G. Strickley, Chandrasekar Venkataramani, Jeff Zablocki
Life of this patent
Estimating the term…
Abstract
Disclosed are novel compounds having the structure of Formula (I): which are useful for treating a human for dependence upon substances of addiction, for example addiction to a dopamine-producing agent such as cocaine, morphine, amphetamines, nicotine, and/or alcohol. Also disclosed are pharmaceutical compositions comprising a therapeutically effective amount of a compound of Formula (I) and methods of using the compounds of Formula (I) in the treatment of addiction to a dopamine-producing agent.
Claims26
A compound of formula (Ib)
- wherein:
- R1 is hydrogen, C1-6 alkyl, —CH2OR22, —CH2OP(O)(OR20)(OR21);
- R2 is hydrogen, cyano, C1-6 alkyl, C3-C6 cycloalkyl, or halo;
- each of R3, R4, R5, R6, R9, R10, R11, R12 and R13 is independently hydrogen, halo, C1-C6 alkyl, hydroxyl, or —CH2OR22;
- R7 is hydrogen or C1-6 alkyl;
- each of R20 and R21 is independently Na+, Li+, K+, hydrogen, or C1-6 alkyl;
- each R22 is independently hydrogen, C1-C6 alkyl, C3-C6 cycloalkyl, phenyl or benzyl;
- or
- a pharmaceutically acceptable salt, single stereoisomer, mixture of stereoisomers, or tautomer thereof.
A compound represented by the structure:
- or a pharmaceutically acceptable salt, or tautomer thereof.
A compound represented by the structure:
A compound represented by the structure:
- or a pharmaceutically acceptable salt, ester, or tautomer thereof.
A compound selected from the group consisting of:
- 2,6-dichloro-4-(2-methoxyethoxy)-N-(4-(2-oxo-1,2-dihydropyridin-4-yl)benzyl)benzamide;
- 2,6-dichloro-N-[4-(2-oxo-1,2-dihydro-pyridin-4-yl)-benzyl]-benzamide;
- 2-chloro-3-fluoro-N-(4-(2-oxo-1,2-dihydropyridin-4-yl)benzyl)benzamide;
- 2-chloro-6-methyl-N-(4-(2-oxo-1,2-dihydropyridin-4-yl)benzyl)benzamide;
- 2,6-dimethyl-N-(4-(2-oxo-1,2-dihydropyridin-4-yl)benzyl)benzamide;
- 2,6-dichloro-N-[4-(6-methyl-2-oxo-1,2-dihydro-pyridin-4-yl)-benzyl]-benzamide;
- 2-chloro-3,6-difluoro-N-(4-(2-oxo-1,2-dihydropyridin-4-yl)benzyl)benzamide;
- 2,6-dichloro-N-(3-methyl-4-(2-oxo-1,2-dihydropyridin-4-yl)benzyl)benzamide);
- 2,6-dichloro-N-(4-(1-methyl-2-oxo-1,2-dihydropyridin-4-yl)benzyl)benzamide;
- 2,6-difluoro-N-(4-(2-oxo-1,2-dihydropyridin-4-yl)benzyl)benzamide;
- 2-chloro-6-fluoro-N-(4-(2-oxo-1,2-dihydropyridin-4-yl)benzyl)benzamide;
- 2,6-dichloro-N-(2-fluoro-4-(2-oxo-1,2-dihydropyridin-4-yl)benzyl)benzamide;
- 2,6-dichloro-N-(4-(5-fluoro-2-oxo-1,2-dihydropyridin-4-yl)benzyl)benzamide;
- and
- phosphoric acid mono-(4-{4-[(2,6-dichloro-benzoylamino)-methyl]-phenyl}-2-oxo-2H-pyridin-1-ylmethyl)ester;
- or
- a pharmaceutically acceptable salt, single stereoisomer, mixture of stereoisomers, or tautomer thereof.
A pharmaceutical composition comprising a compound represented by the structure:
- or a pharmaceutically acceptable salt, or tautomer thereof, and a pharmaceutically acceptable carrier.
A pharmaceutical composition comprising a compound represented by the structure:
- or a pharmaceutically acceptable salt, or tautomer thereof, and a pharmaceutically acceptable carrier.
Dependencies are inferred from the claim text.